Literature DB >> 7691698

Follow-up examination schedule of postoperative HCC patients based on tumor volume doubling time.

S Okada1, N Okazaki, H Nose, K Aoki, N Kawano, J Yamamoto, K Shimada, T Takayama, T Kosuge, S Yamasaki.   

Abstract

The tumor volume doubling time of 27 recurrent hepatocellular carcinoma nodules measuring < or = 2.0 cm in diameter discovered after hepatectomy in 19 patients was analyzed by ultrasonography for 31 to 331 days. The tumor volume doubling time ranged from 39 to 420 days before specific treatment, with a mean of 112 days and a median of 80 days. It correlated with age and intrahepatic site of recurrence, which was sometimes the same lobe as that of the prior hepatocellular carcinoma, sometimes not. The tumor volume doubling time also tended to correlate with hepatitis C antibody status and initial tumor diameter. The tumor volume doubling time was, however, independent of sex, hepatitis B surface antigen status, number of recurrent tumors, initial serum alpha-fetoprotein level, interval between hepatectomy and recurrence detection, and associated liver disease. On the basis of the shortest tumor volume doubling time of the recurrent hepatocellular carcinoma nodules, we recommend that US and/or CT be performed at least every four months to screen for small recurrent carcinomas in postoperative patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691698

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Surveillance for hepatocellular carcinoma: in whom and how?

Authors:  Hashem B El-Serag; Jessica A Davila
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

2.  Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.

Authors:  Hesam Tavakoli; Ann Robinson; Benny Liu; Taft Bhuket; Zobair Younossi; Sammy Saab; Aijaz Ahmed; Robert J Wong
Journal:  Dig Dis Sci       Date:  2017-05-04       Impact factor: 3.199

Review 3.  Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Authors:  Nicole E Rich; Amit G Singal
Journal:  Hepatology       Date:  2022-01-18       Impact factor: 17.425

4.  Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic.

Authors:  Myron J Tong; Hai-En Sun; Carlos Hsien; David S K Lu
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

5.  Applying reinforcement learning techniques to detect hepatocellular carcinoma under limited screening capacity.

Authors:  Elliot Lee; Mariel S Lavieri; Michael L Volk; Yongcai Xu
Journal:  Health Care Manag Sci       Date:  2014-10-12

6.  A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma.

Authors:  Ruben Amoros; Ruth King; Hidenori Toyoda; Takashi Kumada; Philip J Johnson; Thomas G Bird
Journal:  Metron       Date:  2019-05-30

7.  A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.

Authors:  Akihiko Osaki; Takeshi Suda; Kenya Kamimura; Atsunori Tsuchiya; Yasushi Tamura; Masaaki Takamura; Masato Igarashi; Hirokazu Kawai; Satoshi Yamagiwa; Yutaka Aoyagi
Journal:  Cancer Med       Date:  2013-02-03       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.